GlassScriptPhysician profile
Christopher Homsi
NPI 1396487104
$3,891.44
in general payments reported to CMS, 2019-2025
20 companies · $1,592 in 2025
The $1,592 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $900 · 2024: $1,399 · 2025: $1,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,867 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,866.74 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,084.37 | 2023-2025 | |
| Ucb, INC. | $636.31 | 2023-2025 | Zilbrysq, Briviact, Rystiggo |
| Emd Serono, INC. | $436.37 | 2023-2025 | Mavenclad |
| Alexion Pharmaceuticals, INC. | $354.31 | 2023-2025 | Ultomiris, Soliris |
| Novartis Pharmaceuticals Corporation | $281.00 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $228.48 | 2024-2025 | Ingrezza |
| Mdd US Operations, LLC | $174.62 | 2024-2025 | Apokyn, Gocovri |
| Sk Life Science, INC. | $169.76 | 2023-2025 | |
| Eisai INC. | $132.72 | 2024-2025 | |
| Genzyme Corporation | $93.72 | 2023-2024 | |
| Biogen, INC. | $83.64 | 2024-2025 | Vumerity, Tysabri |
| Acadia Pharmaceuticals INC | $45.18 | 2023-2025 | Nuplazid |
| Genentech USA, INC. | $35.43 | 2024-2025 | Ocrevus, Ocrevus Zunovo |
| Takeda Pharmaceuticals U.S.A., INC. | $33.62 | 2024-2025 | Hyqvia |
| Jazz Pharmaceuticals INC. | $29.91 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $17.15 | 2024 | Sunosi |
| Astrazeneca Pharmaceuticals LP | $15.43 | 2025 | Wainua |
| Argenx US, INC. | $15.32 | 2025 | Vyvgart |
| Lilly USA, LLC | $14.09 | 2024 | Kisunla, Amyvid |
| Supernus Pharmaceuticals, INC. | $10.01 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Homsi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.